Enterprise Value

-19.78M

Cash

37.27M

Avg Qtr Burn

-7.213M

Short % of Float

0.07%

Insider Ownership

2.82%

Institutional Own.

10.17%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
WP1220 Details
Cutaneous T cell lymphoma, Blood cancer, Cancer, T-cell lymphoma

Phase 2

Update

WP1066 (p-STAT3 inhibitor) Details
Cancer, Brain tumor, Solid tumor/s, Glioma

Phase 2

Initiation

Annamycin + Ara-C Details
Blood cancer, Cancer, Acute myeloid leukemia

Phase 1/2

Data readout

WP1066 (p-STAT3 inhibitor) Details
Brain tumor, Solid tumor/s, Glioblastoma, Cancer

Phase 1/2

Data readout

Annamycin Details
Soft tissue sarcoma, Solid tumor/s, Cancer, Lung Metastases, Sarcoma

Phase 1/2

Data readout

Phase 1b

Update